EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effects of allisartan‐isoproxil‐based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia

Ningling Sun iD, Hongyi Wang

The Journal of Clinical Hypertension · 2024

DOI: 10.1111/jch.14773 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, 2024. Verfasst von Ningling Sun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hypertension, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Hypertension, Hyperuricemia, Biphenyl Compounds, Imidazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microalbuminuria and hyperuricemia management are crucial for the integrated management of hypertensive patients. This retrospective post hoc analysis aims to evaluate the optimal allisartan‐isoproxil‐based combination regimen for hypertensive patients with microalbuminuria or hyperuricemia. A total of 460 hypertensive patients with microalbuminuria and 486 hypertensive patients with hyperuricemia were included in this study. All patients were initially treated with allisartan‐isoproxil for 4 weeks. Thereafter, patients with blood pressure (BP) < 140/90 mmHg continued the monotherapy for 8 weeks; patients with BP ≥140/90 mmHg were randomly assigned in a 1:1 ratio to receive allisartan‐isoproxil + amlodipine (Group A + C) or allisartan‐isoproxil + indapamide (Group A + D) for 8 weeks. The changes of BP, urinary albumin and serum uric acid (UA) were measured. In patients with microalbuminuria, the urinary albumin/creatinine ratio (UACR) significantly decreased by 10.4 mg/g in Group A + C (vs. baseline p = .0035) and 24.2 mg/g in Group A + D (vs baseline p < .0001), intergroup p = NS. In patients with hyperuricemia, serum UA level decreased by 44.5 µmol/L in Group A + C (vs. baseline p = .0003), but increased by 27.2 µmol/L in Group A + D (vs. baseline p = .0167), intergroup p < .0001. The results suggest that for hypertensive patients with microalbuminuria, angiotensin receptor blocker (ARB) + calcium channel blocker (CCB) or ARB+ diuretic both are good choices based on their improvement of microalbuminuria and BP. But for patients with hyperuricemia, ARB + diuretic may further increase the level of UA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionHyperuricemiaBiphenyl CompoundsImidazolesHumansAntihypertensive AgentsAngiotensin Receptor AntagonistsRetrospective StudiesUric AcidAngiotensin-Converting Enzyme InhibitorsAmlodipineCalcium Channel BlockersBlood PressureDiureticsAlbuminuriaAlbuminsDrug Therapy, Combination

Stichwörter der Autor:innen

allisartan-isoproxilcombination regimenhypertensionhyperuricemiamicroalbuminuria

Substanzen

Antihypertensive AgentsAngiotensin Receptor AntagonistsUric AcidAngiotensin-Converting Enzyme InhibitorsAmlodipineCalcium Channel Blockersallisartan isoproxilDiureticsAlbuminsBiphenyl Compounds

Autor:innen und Institutionen

  • Department of Hypertension, Peking University People's Hospital, Beijing, China.

ORCID-Profile: Ningling Sun

Zitieren

APA

Sun, N., & Wang, H. (2024). Effects of allisartan‐isoproxil‐based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14773

Vancouver

Sun N, Wang H. Effects of allisartan‐isoproxil‐based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia. The Journal of Clinical Hypertension. 2024. doi:10.1111/jch.14773

BibTeX
@article{Sun2024,
  author = {Sun, Ningling and Wang, Hongyi},
  title = {Effects of allisartan‐isoproxil‐based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia},
  journal = {The Journal of Clinical Hypertension},
  year = {2024},
  doi = {10.1111/jch.14773}
}
Kostenlos starten →